Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder

Neuropsychopharmacology

Volumn 38, Issue 4, 2013, Pages 664-672

  Jakobsson, Joel ^a   Zetterberg, Henrik ^a   Blennow, Kaj ^a   Johan Ekman, Carl ^b   Johansson, Anette G M ^b   Landén, Mikael ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

amyloid precursor protein; biomarkers; bipolar disorder; cerebrospinal fluid; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BIOLOGICAL MARKER; LAMOTRIGINE; LITHIUM; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TAU PROTEIN; VALPROIC ACID;

ADULT; ALZHEIMER DISEASE; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; NERVE DEGENERATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BIOLOGICAL MARKERS; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 84873715194     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.231     Document Type: Article

References (46)

1. Bailey AR, Giunta BN, Obregon D, Nikolic WV, Tian J, Sanberg CD et al (2008). Peripheral biomarkers in Autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis. Int J Clin Exp Med 1: 338-344.
2. Belmaker RH (2004). Bipolar disorder. N Engl J Med 351: 476-486.
3. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M et al 2011). Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35: 804-817.
4. Blennow K, Hampel H, Weiner M, Zetterberg H (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131-144.
5. Bradshaw NJ, Porteous DJ (2012). DISC1-binding proteins in neural development, signalling and schizophrenia. Neuropharmacology 62: 1230-1241.
6. Cavanagh JT, Van Beck M, Muir W, Blackwood DH (2002). Casecontrol study of neurocognitive function in euthymic patients with bipolar disorder: an association with mania. Br J Psychiatry 180: 320-326.
7. Cooper B, Holmes C (1998). Previous psychiatric history as a risk factor for late-life dementia: a population-based case-control study. Age Ageing 27: 181-188.
8. Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalves CA et al (2006). Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 398 215-219.
9. Damadzic R, Shuangshoti S, Giblen G, Herman MM (2002). Neuritic pathology is lacking in the entorhinal cortex, subiculum and hippocampus in middle-aged adults with schizophrenia, bipolar disorder or unipolar depression. Acta Neuropathol 103: 488-494.
10. Ekman CJ, Lind J, Ryden E, Ingvar M, Landen M (2010). Manic episodes are associated with grey matter volume reduction-a voxel-based morphometry brain analysis. Acta Psychiatr Scand 122: 507-515.
11. Fioravanti M, Carlone O, Vitale B, Cinti ME, Clare L (2005). A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol Rev 15: 73-95.
12. Frisoni GB, Prestia A, Geroldi C, Adorni A, Ghidoni R, Amicucci G et al 2011). Alzheimer's CSF markers in older schizophrenia patients. Int J Geriatr Psychiatry 26: 640-648.
13. Hernandez F, Avila J (2007). Tauopathies. Cell Mol Life Sci 64: 2219-2233.
14. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M et al (2006). Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 103: 5161-5166.
15. Jope RS 2011). Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 4: 16.
16. Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM (2008). Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 65: 1017-1032.
17. Konarski JZ, McIntyre RS, Kennedy SH, Rafi-Tari S, Soczynska JK, Ketter TA (2008). Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord 10: 1-37.
18. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M et al (2010). Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J 29: 3408-3420.
19. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J et al (2010). Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 15: 138-145.
20. Martinez-Aran A, Vieta E, Colom F, Reinares M, Benabarre A, Gasto C et al (2000). Cognitive dysfunctions in bipolar disorder: evidence of neuropsychological disturbances. Psychother Psychosom 69: 2-18.
21. Martinez-Aran A, Vieta E, Colom F, Torrent C, Reinares M, Goikolea JM et al (2005). Do cognitive complaints in euthymic bipolar patients reflect objective cognitive impairment? Psychother Psychosom 74: 295-302.
22. Martinez-Aran A, Vieta E, Reinares M, Colom F, Torrent C, Sanchez-Moreno J et al (2004). Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 161: 262-270.
23. Mattsson N, Bremell D, Anckarsater R, Blennow K, Anckarsater H, Zetterberg H et al (2010a). Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurol 10: 51.
24. Mattsson N, Bremell D, Anckarsater R, Blennow K, Anckarsater H, Zetterberg H et al (2010b). Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurol 10: 51.
25. Mattsson N, Savman K, Osterlundh G, Blennow K, Zetterberg H (2010c). Converging molecular pathways in human neural development and degeneration. Neurosci Res 66: 330-332.
26. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA et al 2011). Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68: 241-251.
27. Morris M, Maeda S, Vossel K, Mucke L 2011). The many faces of tau. Neuron 70: 410-426.
28. Olsson SK, Samuelsson M, Saetre P, Lindstrom L, Jonsson EG, Nordin C et al (2010). Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci 35: 195-199.
29. Perneczky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, Forstl H et al 2011). CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology 77: 35-38.
30. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003). GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423: 435-439.
31. Pomara N, Bruno D, Sarreal AS, Hernando RT, Nierenberg J, Petkova E et al (2012). Lower CSF Amyloid Beta Peptides and Higher F2-Isoprostanes in Cognitively Intact Elderly Individuals With Major Depressive Disorder. Am J Psychiatry 169: 523-530.
32. Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F et al (2008). Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 205: 2781-2789.
33. Ray B, Long JM, Sokol DK, Lahiri DK 2011). Increased secreted amyloid precursor protein-alpha (sAPPalpha) in severe autism: proposal of a specific, anabolic pathway and putative biomarker. PLoS One 6: e20405.
34. Robinson LJ, Thompson JM, Gallagher P, Goswami U, Young AH, Ferrier IN et al (2006). A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 93: 105-115.
35. Rosen C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N et al (2012). Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer's disease. Neuromolecular Med 14: 65-73.
36. Ryden E, Johansson C, Blennow K, Landen M (2009a). Lower CSF HVA and 5-HIAA in bipolar disorder type 1 with a history of childhood ADHD. J Neural Transm 116: 1667-1674.
37. Ryden E, Thase ME, Straht D, Aberg-Wistedt A, Bejerot S, Landen M (2009b). A history of childhood attention-deficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD. Acta Psychiatr Scand 120: 239-246.
38. Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR et al (2003). Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEPBD). Biol Psychiatry 53: 1028-1042.
39. Sanchez-Moreno J, Martinez-Aran A, Colom F, Scott J, Tabares-Seisdedos R, Sugranyes G et al (2009). Neurocognitive dysfunctions in euthymic bipolar patients with and without prior history of alcohol use. J Clin Psychiatry 70: 1120-1127.
40. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M (1993). Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 88: 791-804.
41. Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA et al (2005). Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same? Ann Neurol 58: 139-142.
42. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20): 22-33; quiz 34-57.
43. Turner PR, O'Connor K, Tate WP, Abraham WC (2003). Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70: 1-32.
44. Young-Pearse TL, Suth S, Luth ES, Sawa A, Selkoe DJ (2010). Biochemical and functional interaction of disrupted-in-schizophrenia 1 and amyloid precursor protein regulates neuronal migration during mammalian cortical development. J Neurosci 30: 10431-10440.
45. Zarate CA Jr., Tohen M, Land M, Cavanagh S (2000). Functional impairment and cognition in bipolar disorder. Psychiatr Q 71: 309-329.
46. Zhang YW, Thompson R, Zhang H, Xu H 2011). APP processing in Alzheimer's disease. Mol Brain 4: 3.